Day: September 27, 2023

Reference is made to previous announcements on August 30th and September 2nd in relation to the sale of 100% of the share capital of IS UK to Espersen A/S. Completion of the sale was finalized today, on September 27th . In line with previous announcements, ISI has now converted intercompany loans into equity and injected further equity to net out negative equity balance and compensate for operating losses in Q3. After the equity injection, the book value of equity at completion will amount to £0.3m. According to the agreement the sales price for the 100% share is £1,000 meaning that the sales loss of the shares will be £0.3m. Completion accounts will be prepared based on September interim accounts and a completion adjustment will be made in October, based on these accounts. The negative impact on ISI P&L and equity during 2023 is...

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 – 5, 2023 at the San Diego Convention Center in San Diego, CA. Abstract #1351: Identifying IL-27 dependent biomarkers in lymphocytes, NK cells, and myeloid cells in peripheral blood and the tumor microenvironmentDate and Time: Friday, November 3, 9 a.m.–7 p.m. Pacific Daylight Time (PDT)Location: Exhibit Halls A and B1 – San Diego Convention Center Abstract #468: Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 statusDate and Time: Saturday, November 4, 9 a.m.–8:30...

Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ CellsDemonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune Cells Evaluation of Cloak™ Technology to Engineer Allogeneic Cells from Detection by the Host Immune SystemPreclinical Validation of ALLO-182, an AlloCAR T™ Candidate Targeting Claudin18.2 for the Treatment of Gastric and Pancreatic CancersSOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced three preclinical poster presentations at the Society for Immunotherapy of Cancer...

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of six abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 1-5, 2023, both in San Diego, CA and virtually. Presentation Details: Title: Product Characteristics and Clinical Trial Design for T-Plex, a Multiplexed, Enhanced T cell Receptor-Engineered T cell Therapy for Solid TumorsAuthors: Shrikanta Chattopadhyay, Antoine J Boudot, Ribhu Nayar, Hannah Bader, Andrew Ferretti, Tary Traore, Nancy Nabilsi, Jenny Tadros, Badr Kiaf, Yifan Wang, Victor Ospina, Alok Das Mahopatra, Zhonghua...

MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with a comparison of NK cell redirected by the Company’s innate cell engagers (ICE®) versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 1-5, 2023 in San Diego, California. Details of the poster presentation are as follows: Title: Redirecting NK cell cytotoxicity by Innate Cell Engagers: A differentiated and innovative approach compared to CAR-NK cells Presenting Author: Sonya Ioana Ciulean Abstract Number: 329 Poster Presentation Time: Friday, Nov. 3, 2023,...

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to unveil updated clinical and translational data, along with insights on agenT-797’s distinct mechanism of action in solid tumors. A poster will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting on November 1-5, 2023. Presentation Details Title: Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer Presenting Author: Marco Purbhoo, Ph.D., Head of Translational Research, MiNK Therapeutics Abstract...

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today two poster presentations highlighting the company’s Immuno-STAT™ platform and lead clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting (SITC 2023). The conference will be held in San Diego, California and virtually on November 1-5, 2023. Presentation DetailsTitle: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patientsAbstract...

– Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies – – Abstracts include new preclinical data demonstrating ongoing progress from collaboration with BlueRock Therapeutics and new technology development to enable Senti’s future oncology pipeline products – SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held November 1-5, 2023, in San Diego, CA. Information...

Pittsburgh, PA, Sept. 27, 2023 (GLOBE NEWSWIRE) — Himalaya Technologies, Inc. (OTC: HMLA) is providing an update to investors regarding its completed corporate actions review process with FINRA and plans for growth: HMLA Completes FINRA Corporate Actions Review* On June 14, 2023, we were notified that we cured FINRA’s “potential prong issue” regarding our need for a quorum for a June 28, 2021 shareholder vote which authorized our name change to Himalaya Technologies, Inc. from Homeland Resources Ltd., increased our authorized common shares and authorized Series A Preferred shares, and created new classes of Series B Preferred stock and Series C Preferred stock to allow for mergers and acquisitions and future corporate actions. Our shareholder actions, appointed management team members and Directors of our Board, and previously...

ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023. Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency Abstract Number: 274 Location: Exhibit Halls A and B1Date and Time: Saturday, November 4, 2023, 9:00 a.m. – 8:30 p.m. Title: Allogeneic CAR T cells targeting Liv-1 for Breast Cancer Abstract Number: 324 Location: Exhibit Halls A and B1Date and...